Biology Reference
In-Depth Information
Fig. 29.2 Fluorescence image of C2C12 myotube treated with 20 mM taurine in the Ca 2+ chelator
nifedipine treatment ( a ) and taut siRNA transfection ( b ) and the expression level of MCIP1 mRNA
in the myotube treated with taurine and nifedipine ( c ). ( a , c) C2C12 cells were exposed to differ-
entiation medium containing 20 mM taurine with or without 10 mM nifedipine for 5 days. Myosin
heavy-chain protein in myotube was immunohistochemically stained with anti-MHC and FITC-
conjugate IgG antibodies ( c ). C2C12 cells transfected with either control or taut siRNA and GFP
vector were differentiated with 20 mM taurine ( c ). The mRNA expression level of MCIP1 was
quantified by real-time PCR and shown as the relative ratio to undifferentiated myoblast. The dif-
ferentiated myotube was detected by the transfected GFP. Data are shown as the mean ± SD and
* P < 0.05, † P < 0.001(vs. myoblast) by the unpaired Student's t -test and one-way AVOVA multi-
ple comparison test, respectively
treated with and without nifedipine was significantly reduced by taurine treatment
(Fig. 29.2b ). Similarly, FK-506 treatment in the C2C12 cells markedly reduced
the enhancement of differentiation to myotube by taurine treatment (data not
shown).
In Fig. 29.2c , the silencing taut gene using siRNA technique inhibited the dif-
ferentiation to myotube in the C2C12 cells treated with 20 mM taurine compared to
that in the control siRNA-transfected cells. Furthermore, the effect of taurine on the
differentiation to myotube was significantly reduced by b-alanine treatment in a
dose-dependent manner (data no shown).
Search WWH ::




Custom Search